ORS 689.800: Opioid overdose; treatment; administration of short-acting opioid antagonist; liability; rules.
Edition: 2025 EditionEffective: 2026-01-01Last verified: 2026-09-07
(1) As used in this section: (a) “Kit” means a package of one or more doses of a short-acting opioid antagonist and the necessary medical supplies to administer the short-acting opioid antagonist. (b) “Opioid” means a natural, synthetic or semisynthetic chemical that interacts with opioid receptors on nerve cells in the body and brain to reduce the intensity of pain signals and feelings of pain. (c) “Opioid overdose” means a medical condition that causes depressed consciousness, depressed respiratory function or the impairment of vital bodily functions as a result of ingesting opioids. (d) “Short-acting opioid antagonist” means any short-acting drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose. (2) Notwithstanding any other provision of law, a pharmacy, a health care professional, a pharmacist with prescription and dispensing privileges, a law enforcement officer, a firefighter, an emergency medical services provider or any other person designated by the State Board of Pharmacy by rule may: (a) Distribute and administer a short-acting opioid antagonist and distribute the necessary medical supplies to administer the short-acting opioid antagonist; (b) Distribute multiple kits to: (A) An individual who has experienced an opioid overdose or is likely to experience an opioid overdose; (B) Family members of an individual described in subparagraph (A) of this paragraph; and (C) Any other individual who requests one or more kits; and (c) Distribute multiple kits to social service agencies under ORS 689.804 or to other persons who work with individuals who have experienced an opioid overdose. The social services agencies or other persons may redistribute the kits to individuals likely to experience an opioid overdose or to family members of the individuals. (3)(a) A person acting in good faith, if the act does not constitute wanton misconduct, is immune from criminal and civil liability for any act or omission of an act committed during the course of distributing and administering a short-acting opioid antagonist and distributing the necessary medical supplies to administer the short-acting opioid antagonist under this section. (b) A person acting in good faith is immune from criminal and civil liability for the person’s failure or refusal to distribute or administer a short-acting opioid antagonist or distribute the necessary medical supplies to administer a short-acting opioid antagonist under this section, if the person’s failure or refusal does not constitute wanton misconduct. [Formerly 689.681]
This rule cites
- ORS 689.804 — resolved
Cited by
- ORS 339.867: Definitions for ORS 339.869 and 339.870.
- ORS 430.263: Provision of opioid overdose reversal medication upon release or discharge from facility that provides detoxification services; civil immunity.
- ORS 441.698: Provision of opioid reversal medication and supplies upon discharge or transfer of resident who received addiction treatment.
- ORS 443.454: Provision of opioid overdose reversal medication upon discharge, release or transfer of resident from facility where resident received addiction treatment.
- ORS 689.804: Administration of short-acting opioid antagonist by certain persons; rules.
- ORS 689.806: Notice of availability of short-acting opioid antagonist; rules.
- ORS 689.808: Short-acting opioid antagonist standing order; liability; rules.
- ORS 689.811: Publicly accessible short-acting opioid antagonist; administration; liability; rules.
- OAR 309-040-0390: Standards and Practices for Care and Services
- OAR 581-021-0037: Administration of Medication
- OAR 847-035-0030: Scope of Practice
Official source: https://www.oregonlegislature.gov/bills_laws/ors/ors689.html